Skip to main content

Table 1 Clinical parameters, CBC and immunophenotypic markers of CLL patients

From: Evaluation of immunophenotypic markers and clinico-hematological profile in chronic lymphocytic leukemia: implications for prognosis

Characteristics CLL patients (n = 35)
Age, mean (range) 64.34 (36–86 years)
Gender, n (%)
 Male 24 (68.6%)
 Female 11 (31.4%)
Rai staging system, n (%)
 0 8 (22.9%)
 I 3 (8.6%)
 II 3 (8.6%)
 III 10 (28.6%)
 IV 11 (31.4%)
Modified Rai staging system, n (%)
 Low-risk group 8 (22.9%)
 Intermediate-risk group 6 (17.1%)
 High-risk group 21 (60.0%)
Binet staging system, n (%)
 A 12 (34.3%)
 B 2 (5.7%)
 C 21 (60.0%)
Splenomegaly, n (%)
 Yes 19 (54.3%)
 No 16 (45.7%)
Lymphadenopathy, n (%)
 Yes 11 (31.4%)
 No 24 (68.6%)
Hepatomegaly, n (%)
 Yes 0 (0%)
 No 35 (100%)
WBC count × 103/μL, median (IQR) 45 (22–112)
Platelets × 103/μL, median (IQR) 131 (95–167)
 ≥ 100 n, 24 (68.6%)
 < 100 n, 11 (31.4%)
Hemoglobin g/dL, median (IQR) 10.7 (9.9–13.2)
 ≥ 11 n, 15 (42.9%)
 < 11 n, 20 (57.1%)
ALC × 103/μL, median (IQR) 35.9 (18.4–101)
ANC × 103/μL, median (IQR) 4.2 (3.6–11)
PLR × 103/μL, median (IQR) 3.2 (1.3–8.1)
NLR × 103/μL, median (IQR) 0.15 (0.09–0.18)
CD38 (%), median (IQR) 3.0 (1.0–6.0)
CD25 (%), median (IQR) 6.0 (1.5–10.0)
Double positive CD56/CD117, median (IQR) 0.1 (0.1–0.4)
  1. CLL chronic lymphocytic leukemia, WBC white blood cell, IQR interquartile range, ALC absolute lymphocyte count, ANC absolute neutrophil count, PLR platelet/lymphocyte ratio, NLR neutrophil/lymphocyte ratio